ADMA (asymmetric dimethylarginine) is a cardiovascular risk factor and an endogenous inhibitor of NOS (nitric oxide synthase). ADMA is metabolized by DDAHs (dimethylarginine dimethylaminohydrolases). ADMA levels are increased in cardiovascular disorders associated with abnormal angiogenesis but the mechanisms are poorly understood. Recent studies show that altering ADMA metabolism in vivo and i...

Postmenopausal Women To the Editor: We read with great interest the recent article by Holden et al1 dealing with the relationship between estrogen and asymmetric dimethylarginine (ADMA) metabolism in postmenopausal women. The results of their study demonstrated that hormone replacement therapy significantly decreased plasma ADMA levels in postmenopausal women. In an in vitro study, Holden et al...

Asymmetric Dimethylarginine and Cerebrovascular Disorders in Humans To the Editor: We read with great interest the recent article by Dr Kielstein and colleagues1 dealing with the cerebrovascular effects of the endogenous nitric oxide (NO) synthase inhibitor, asymmetric dimethylarginine (ADMA), in humans. The results of their study demonstrated that systemic infusion of ADMA increased arterial s...

Recent studies have shown that asymmetric dimethylarginine (ADMA), a nitric oxide synthase inhibitor, is increased in hypertension and chronic kidney disease. However, little is known about the effects of hypertension per se on ADMA metabolism. The purpose of this study was to test the hypothesis that ANG II-induced hypertension, in the absence of renal injury, is associated with increased oxid...

l-Arginine (Arg) is oxidized to l-citrulline and nitric oxide (NO) by the action of endothelial nitric oxide synthase (NOS). In contrast, protein-incorporated Arg residues can be methylated with subsequent proteolysis giving rise to methylarginine compounds, such as asymmetric dimethylarginine (ADMA) that competes with Arg for binding to NOS. Most ADMA is degraded by dimethylarginine dimethyami...

Symmetrical dimethylarginine (SDMA) is the structural isomer of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine. Whereas the major route of asymmetric dimethylarginine elimination is the hydrolytic degradation by dimethylarginine dimethylaminohydrolase, SDMA is eliminated by renal excretion. SDMA does not directly inhibit NOS but is a competitor of arginine tran...

Asymmetric dimethylarginine (ADMA) is involved in the pathogenesis of hypertension and atherosclerosis by inhibiting the generation of nitric oxide, an endogenous vasculoprotective molecule. Determination of ADMA helps to predict a patient`s probability of experiencing death or cardiovascular disease. A novel competitive ADMA-ELISA that has recently been developed and validated by us is a usefu...

© 2015 The Authors; Tabriz University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Asymmetric dimethylarginine and homocysteine in exudative age-rela...

Increased asymmetric dimethylarginine level after antiepi-leptic drug treatment may be independent of the changes in plasma homocysteine level Dear Editor, We have read the recent article by Sniezawska and colleagues with great interest. 1 The authors investigated the frequency of polymorphism in the MTHFR (C677T), MTR (A2756G), and MTHFD1 (G1958A) genes and analysed the levels of homocysteine ...